← Back to all trials
Completed
NCT07229820
Efficacy and Safety of ZSP1273 in Adolecent 12-17 Years Old With Influenza A
Conditions: Influenza A
Sex: All
Ages: 12 Years – 17 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 157
Sponsor: Guangdong Raynovent Biotech Co., Ltd
Location: Ruijin Hospital Shanghai
Summary
This trial is conducted in China. This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of ZSP1273 in the treatment of Acute Uncomplicated influenza A in adolescents.
Eligibility Criteria
Inclusion Criteria:
1. Participants and their guardians who are able to understand the study and comply with all study procedures, and willing to provide written informed consent/assent prior to the predose examinations appropriately.
2. Male or female participants aged ≥ 2 to ≤11 years at the time of signing the informed consent form.
3. Participants with a diagnosis of influenza virus infection confirmed by all of the following:
1. Positive rapid antigen test (RAT) for influenza with nasal or throat swabs;
2. The time interval between the onset of symptoms and enrollment is 48 hours or less;
3. Fever ≥ 38ºC (axillary temperature); and at least one following respiratory symptoms associated with influenza virus infection is present
Exclusion Criteria:
1. Participants with severe influenza virus infection;
2. Participants with any medical history in gastrointestinal that interferes with the absorption of drugs;
3. Immunodeficiency,including malignant tumor,organ or marrow transplant,human immunodeficiency virus \[HIV\] infection,or patients receiving immunosuppressant therapy 3 months prior to enrollment;
4. Have received any other investigational products within 3 months prior to dosing;
5. Positive urine pregnancy test;
6. Participants with concurrent infections requiring antimicrobial therapy;
7. Participants who are considered inappropriate for the study by the investigator.
Source: ClinicalTrials.gov (NCT07229820). StuddyBuddy aggregates publicly available trial information.